Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury
- PMID: 35192075
- DOI: 10.1007/s10557-022-07329-9
Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury
Abstract
Purpose: Recombinant apyrase (AZD3366) increases adenosine production and ticagrelor inhibits adenosine reuptake. We investigated whether intravenous AZD3366 before reperfusion reduces myocardial infarct size (IS) and whether AZD3366 and ticagrelor have additive effects.
Methods: Sprague-Dawley rats underwent 30 min ischemia. At 25 min of ischemia, animals received intravenous AZD3366 or vehicle. Additional animals received intravenous CGS15943 (an adenosine receptor blocker) or intraperitoneal ticagrelor. At 24 h reperfusion, IS was assessed by triphenyltetrazolium chloride. Other rats were subjected to 30 min ischemia followed by 1 h or 24 h reperfusion. Myocardial samples were assessed for adenosine levels, RT-PCR, and immunoblotting.
Results: AZD3366 and ticagrelor reduced IS. The protective effect was blocked by CGS15943. The effect of AZD3366 + ticagrelor was significantly greater than AZD3366. One hour after infarction, myocardial adenosine levels significantly increased with AZD3366, but not with ticagrelor. In contrast, 24 h after infarction, adenosine levels were equally increased by AZD3366 and ticagrelor, and levels were higher in the AZD3366 + ticagrelor group. One hour after reperfusion, AZD3366 and ticagrelor equally attenuated the increase in interleukin-15 (an early inflammatory marker after ischemic cell death) levels, and their combined effects were additive. AZD3366, but not ticagrelor, significantly attenuated the increase in RIP1, RIP3, and P-MLKL (markers of necroptosis) 1 h after reperfusion. AZD3366, but not ticagrelor, significantly attenuated the increase in IL-6 and GSDMD-N (markers of pyroptosis) 1 h after reperfusion. At 24 h of reperfusion, both agents equally attenuated the increase in these markers, and their effects were additive.
Conclusions: AZD3366 attenuated inflammation, necrosis, necroptosis, and pyroptosis and limited IS. The effects of AZD3366 and ticagrelor were additive.
Keywords: Adenosine; Animal model; Apyrase; Infarct size; Myocardial infarction; Necroptosis; Necrosis; Pyroptosis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction.Eur Heart J. 2024 May 7;45(17):1553-1567. doi: 10.1093/eurheartj/ehae107. Eur Heart J. 2024. PMID: 38486376
-
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1805-14. doi: 10.1161/ATVBAHA.115.305655. Epub 2015 Jun 4. Arterioscler Thromb Vasc Biol. 2015. PMID: 26044583
-
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine.Cardiovasc Drugs Ther. 2016 Dec;30(6):539-550. doi: 10.1007/s10557-016-6701-2. Cardiovasc Drugs Ther. 2016. PMID: 27830382
-
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion.Cell Physiol Biochem. 2019;53(6):961-981. doi: 10.33594/000000189. Cell Physiol Biochem. 2019. PMID: 31820856
-
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2078-85. doi: 10.1161/ATVBAHA.114.304002. Epub 2014 Jul 10. Arterioscler Thromb Vasc Biol. 2014. PMID: 25012137
Cited by
-
Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.J Cardiovasc Dev Dis. 2023 Jul 17;10(7):303. doi: 10.3390/jcdd10070303. J Cardiovasc Dev Dis. 2023. PMID: 37504559 Free PMC article. Review.
-
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.J Am Heart Assoc. 2024 Jun 4;13(11):e033985. doi: 10.1161/JAHA.123.033985. Epub 2024 May 28. J Am Heart Assoc. 2024. PMID: 38804212 Free PMC article. Clinical Trial.
-
Different types of cell death and their interactions in myocardial ischemia-reperfusion injury.Cell Death Discov. 2025 Mar 5;11(1):87. doi: 10.1038/s41420-025-02372-5. Cell Death Discov. 2025. PMID: 40044643 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous